Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) were first-line
treatments for NSCLC patients with EGFR-mutations. However, about 30% of responders …

The discovery of activating mutations in the epidermal growth factor receptor (EGFR) gene
and the development of EGFR tyrosine kinase inhibitors (TKIs) have led to a paradigm shift …

Objective. This study aimed to compare the efficacy of different first‐line strategies based on
different EGFR mutation types (19 deletion and 21 Leu858Arg mutations). Methods. We …

Enormous efforts have been made to integrate various therapeutic interventions into
multifunctional nanoplatforms, resulting in the advance of nanomedicine. Image-guided drug …

Introduction Plasma cfDNA-based mutation analysis has shown disease-monitoring
potential in various cancers. We assessed the potential of cfDNA-based EGFR mutation …

Background The discovery of the epidermal growth factor receptor (EGFR) and development
of targeted drugs have led to substantial gains in the treatment of non–small cell lung cancer …

Mutations in the epidermal growth factor receptor (EGFR) are common amongst those with
non-small cell lung cancer and represent a major factor in treatment decisions, most notably …

OBJECTIVES To clarify survival outcomes and prognostic factors of patients receiving
epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) as first-line …

Neoadjuvant immunotherapy and chemotherapy have improved the major pathological
response (MPR) in patients with early-stage operable non-small cell lung cancer (NSCLC) …

Chemotherapy, in combination with immune checkpoint blockade (ICB) targeting to
programmed death‐1 (PD‐1) or its ligand PD‐L1, is one of the first‐line treatments for …